Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: The invention provides a dust cap which allows for performing operation test of an optical transceiver without removing the dust cap from the optical transceiver. The dust cap 100 comprises: a connector 110a having an opening on a distal end of the connector 110a, which is pressed into a transmission adapter of the optical transceiver 300; a connector 110b having an opening on a distal end of the connector 110b, which is pressed into a reception adapter of the optical transceiver 300 adjacent to the transmission adapter; a support member 140 connected with proximal ends of the connectors 110a, 110b and configured to support the connectors 110a, 110b; and an optical transmission path 130 configured to pass through the connector 110a, the support member 140, and the connector 110b in that order and to transmit light from the opening of the connector 110a to the opening of the connector 110b.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: The invention provides a dust cap which allows for performing operation test of an optical transceiver without removing the dust cap from the optical transceiver. The dust cap 100 comprises: a connector 110a having an opening on a distal end of the connector 110a, which is pressed into a transmission adapter of the optical transceiver 300; a connector 110b having an opening on a distal end of the connector 110b, which is pressed into a reception adapter of the optical transceiver 300 adjacent to the transmission adapter; a support member 140 connected with proximal ends of the connectors 110a, 110b and configured to support the connectors 110a, 110b; and an optical transmission path 130 configured to pass through the connector 110a, the support member 140, and the connector 110b in that order and to transmit light from the opening of the connector 110a to the opening of the connector 110b.

Abstract: A composite silica glass made light diffusion member includes a dense silica glass, and a porous silica glass which has been layered on the surface of the dense silica glass. The porous silica glass is a porous body and has a homogeneous pore distribution. The porous body has a framework including a plurality of spherical silica glasses, contains a communicating pore part formed by spaces among them, and has a central pore size of 10 to 20 ?m and a porosity of 25 to 40%. The spherical silica glasses have an average diameter of 30 to 100 ?m. An average value of a specific arithmetic average roughness Ra in each of the spherical silica glass exposed on an outer surface of the porous silica glass is 0.8 to 4.0 nm.

Abstract: A sensor device includes a sensor element, a converter, and an output unit. The sensor element includes a sheet-like dielectric layer including an elastomer composition and a top electrode layer and a bottom electrode layer each including an electroconductive composition containing carbon nanotubes. The top and the bottom electrode layers are formed on a top surface and a bottom surface of the dielectric layer, respectively, and are at least partially opposed to each other across the dielectric layer. The at least partially opposed portions of the top and the bottom electrode layers constitute a detection portion, and the dielectric layer reversibly deforms to change an area of a main surface of the dielectric layer. The converter electrically is connected to the sensor element and converts capacitance at the detection portion that varies in accordance with the deformation of the dielectric layer to electric characteristics.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L1-L2-LP-NH—(CH2)n1-La-Lb-Lc or -L1-L2-LP- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the terminal Lc or LP with the nitrogen atom of the amino group at position 1 as the connecting position.

Abstract: An object of the present invention is to provide a sealing member for machine tools which has excellent reliability because excellent sealability can be maintained for a long period of time and which can be manufactured efficiently at low cost. The sealing member for machine tools of the present invention includes a supporting member; a plate-shaped elastic member; and an adhesive layer which bonds the elastic member to the supporting member. The supporting member has a shape of a bent plate-like body, the elastic member is bonded to the supporting member via the adhesive layer laminated on a part of a front face of the elastic member so as to be curved along the bent shape of the supporting member, and a corner portion formed by a back face and one side face of the elastic member is assumed to be an edge portion in contact with an opposite material, and the one side face is formed by cutting.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2—C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2—C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: An analog signal transfer system includes a transmission apparatus including a variable compressor that variably compresses input signals exponentially according to the amplitudes of the input signals; and a reception apparatus including a variable expander that variably expands the compressed signals exponentially according to the amplitudes of the compressed signals.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: An analog signal transfer system includes a transmission apparatus including a variable compressor that variably compresses input signals exponentially according to the amplitudes of the input signals; and a reception apparatus including a variable expander that variably expands the compressed signals exponentially according to the amplitudes of the compressed signals.

Abstract: ML-236B is an inhibitor of HMG-CoA reductase and useful in preparing another such inhibitor, pravastatin. The preparation of ML-236B using an ML-236B-producing microorganism is enhanced using a polynucleotide encoding a gene related to the polyketide synthase cluster occurring in such a microorganism.

Abstract: Polynucleotides, such as DNA, are provided which accelerate the biosynthesis of a HMG-CoA reductase inhibitor, ML-236B, in an ML-236B producing micro-organism when introduced in the ML-236B producing micro-organism. Pravastatin, which is an HM-CoA reductase inhibitor, can be obtained using Streptomyces carbophilus by microbial conversion of ML-236B produced by Pencillium citrinum. The polynucleotides encode a gene (such as micA (polyketide synthase), mlcB (polyketide synthase), micE (efflux pump) or mlcR (transcription factor). Provided are vectors into which such polynucleotides are incorporated; host cells transformed by such vectors; and proteins expressed by such vectors. A method for producing ML-236B using such polynucleotides and/or proteins which comprises recovering ML-236B from a culture of the host cell.

Abstract: ML-236B is an inhibitor of HMG-CoA reductase and useful in preparing another such inhibitor, pravastatin. The preparation of ML-236B using an ML-236B-producing microorganism is enhanced using a polynucleotide encoding a gene related to the polyketide synthase cluster occurring in such a microorganism.